BCL2 and diffuse large B-cell lymphoma: This PDX, obtained from a nodal biopsy performed at relapse in a DLBCL patient treated with first-line R-CHOP chemoimmunotherapy, was characterized by high BCL-2 expression (Figure 4E) and a lack of genomic alterations in TP53. After PDX engraftment, NOD.Cg-PrkdcSCIDIl2rgtm1Wjl/SzJ (NSG) mice were treated with Act D, venetoclax, and idasanutlin (MDM2i) as monotherapy or in combination with different regimens (Act D + venetoclax, idasanutlin + venetoclax, Act D + idasanutlin, and Act D + idasanutlin + venetoclax) for 14 days (Figures 4E–4G).